ClinVar Miner

Submissions for variant NM_000329.3(RPE65):c.246-11A>G

dbSNP: rs905365719
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ClinGen Leber Congenital Amaurosis/early Onset Retinal Dystrophy Variant Curation Expert Panel, ClinGen RCV003770300 SCV004697430 likely pathogenic RPE65-related recessive retinopathy 2024-02-01 reviewed by expert panel curation NM_000329.3(RPE65):c.246-11A>G is a variant within intron 3 adjacent to exon 4. The splicing impact predictor SpliceAI gives scores of 0.48 for splice acceptor loss and 0.39 for splice acceptor gain, which are above the ClinGen LCA / eoRD VCEP recommended threshold of >=0.2 and predict a damaging impact on splicing. RT-PCR of RNA extracted from patient fibroblast-derived iPSCs detected a transcript with cryptic splice site usage introducing a frameshift and a premature termination codon, as well as a smaller amount of wild-type mRNA, consistent with a nearly complete splicing defect and most of the transcript undergoing nonsense-mediated decay (PVS1(RNA)_Strong). This variant has been reported in at least 2 unrelated probands with early-onset severe retinal dystrophy who were compound heterozygous with either the NM_000329.3:c.615_616delCA (p.Ile206Cysfs*27) variant suspected in trans (PMID: 29033008) or the NM_000329.3(RPE65):c.208T>G (p.Phe70Val) variant confirmed in trans (PMID: 33472769, which were previously classified pathogenic or likely pathogenic by the ClinGen LCA / eoRD VCEP (1.5 total points, PM3). At least one proband harboring this variant exhibits a phenotype including abnormal best corrected visual acuity test (1 pt), visual field defect (1 pt), absence of rod response on ERG (0.5 pts), and improvement of FST and rod function following administration of RPE65 gene therapy (8 pts), which together are highly specific for RPE65-related recessive retinopathy (10.5 total points, PMID: 33472769, PP4_Moderate). The variant is present in gnomAD v.2.1.1 at a minor allele frequency of 0.000003988, with 1 allele / 250758 total alleles in the African / African-American population, which is lower than the ClinGen LCA / eoRD VCEP PM2_Supporting threshold of <0.0002 (PM2_Supporting). In summary, this variant meets the criteria to be classified as likely pathogenic for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA/eoRD VCEP: PVS1(RNA)_Strong, PM2_Supporting, PM3, and PP4_Moderate. (VCEP specifications version 1.0.0; date of approval 09/21/2023).
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV002307711 SCV002600350 likely pathogenic Leber congenital amaurosis 2022-10-08 criteria provided, single submitter clinical testing Variant summary: RPE65 c.246-11A>G alters a non-conserved nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. Several computational tools predict a significant impact on normal splicing: Four predict the variant creates a cryptic 3' acceptor site, one predicts the variant abolishes a canonical 3' acceptor site, and three predict the variant weakens a canonical 3' acceptor site. At least one publication reports experimental evidence showing that this variant affects mRNA splicing, resulting in the inclusion of a pseudoexon that causes a frameshift (Tucker_2015). The variant allele was found at a frequency of 4e-06 in 250758 control chromosomes (gnomAD). c.246-11A>G has been reported in the literature as a biallelic genotype in individuals affected with Leber Congenital Amaurosis and Early Onset Retinal Degeneration (e.g. Tucker_2015, Le Meur_2018, Stingl_2022). These data indicate that the variant may be associated with disease. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as likely pathogenic.
Fulgent Genetics, Fulgent Genetics RCV002480862 SCV002776989 likely pathogenic Leber congenital amaurosis 2; Retinitis pigmentosa 20; Retinitis pigmentosa 87 with choroidal involvement 2021-11-08 criteria provided, single submitter clinical testing
Invitae RCV002570428 SCV003523306 pathogenic Leber congenital amaurosis 2; Retinitis pigmentosa 20 2023-05-22 criteria provided, single submitter clinical testing For these reasons, this variant has been classified as Pathogenic. Studies have shown that this variant results in activation of a cryptic splice site and introduces a premature termination codon (PMID: 26364624). The resulting mRNA is expected to undergo nonsense-mediated decay. ClinVar contains an entry for this variant (Variation ID: 973955). This variant is also known as IVS3-11. This variant has been observed in individual(s) with clinical features of autosomal recessive RPE65-related conditions (PMID: 26364624, 29033008, 33472769). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant is present in population databases (no rsID available, gnomAD 0.007%). This sequence change falls in intron 3 of the RPE65 gene. It does not directly change the encoded amino acid sequence of the RPE65 protein. RNA analysis indicates that this variant induces altered splicing and may result in an absent or disrupted protein product.
Baylor Genetics RCV001250681 SCV004209263 likely pathogenic Leber congenital amaurosis 2 2023-06-17 criteria provided, single submitter clinical testing
Laboratory of Genetics in Ophthalmology, Institut Imagine RCV001250681 SCV001425551 pathogenic Leber congenital amaurosis 2 no assertion criteria provided research

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.